Lazabemide (proposed trade names Pakio, Tempium) is a reversible and selective inhibitor of monoamine oxidase B (MAO-B) that was under development as an antiparkinsonian agent but was never marketed.

[1]

This drug article relating to the nervous system is a stub.

You can help Wikipedia by expanding it.